Drug Profile
Angiotensin-1-7 long-acting
Alternative Names: Lanthionine-stabilized angiotensin-(1-7) agonistic peptide; Lanthionine-stablised angiotensin-(1-7) agonistic peptide; PanCyteLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Lanthio Pharma
- Developer Tarix Pharmaceuticals
- Class Angiotensins; Antihypertensives; Antiretrovirals; Hormones; Peptide hormones; Peptides; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Proto-oncogene protein c-mas-1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chemotherapy-induced anaemia; Lung disorders; Neutropenia; Peripheral vascular disorders; Stroke; Thrombocytopenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chemotherapy-induced-anaemia in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neutropenia(Chemotherapy-induced) in USA